Johnson & Johnson (NYSE: JNJ) released two-year data from its Phase 3 ICONIC-TOTAL study of ICOTYDE (icotrokinra) in patients with plaque psoriasis affecting sensitive body areas, presenting the findings at the European Academy of Dermatology and Venereology Congress 2026.

According to the company's press release, 70% of treated patients achieved clear or almost clear skin at Week 112, up from 57% at Week 16. Among patients with site-specific disease, 60% with scalp psoriasis and 89% with genital psoriasis achieved complete skin clearance at Week 112. Patients with hand and/or foot psoriasis showed a 63% complete clearance rate at the same time point. Nail psoriasis improvement, measured by the modified Nail Psoriasis Severity Index, rose from 33% at Week 16 to 71% at Week 112.

Johnson & Johnson said the safety profile through Week 112 remained consistent with earlier findings, with no new safety signals identified. Common reported side effects include headache, nausea, cough, fungal infection, and tiredness.

ICOTYDE is described by the company as the first targeted oral peptide designed to block the IL-23 receptor. It is approved in the U.S. for moderate-to-severe plaque psoriasis in adults and patients 12 years and older weighing at least 40 kg. The drug also holds approvals in Europe, Japan, and China.

"These two-year ICOTYDE results empower physicians to treat high-impact sites, knowing that data support sustained clinical outcomes for patients," said David M. Lee, M.D., Ph.D., Global Immunology Therapeutic Area Head at Johnson & Johnson.

ICOTYDE was jointly discovered through a license and collaboration agreement between Protagonist Therapeutics and Johnson & Johnson, with Johnson & Johnson holding exclusive worldwide rights to develop and commercialize the therapy. The drug is also being studied in psoriatic arthritis, ulcerative colitis, and Crohn's disease.